Why the study?
Obesity has emerged as a major health challenge contributing substantially to the burden of cardiovascular disease.
Do anti-obesity pharmacotherapies like semaglutide and tirzepatide improve cardiovascular outcomes and symptoms in patients with obesity and cardiovascular disease?
Do anti-obesity pharmacotherapies like semaglutide and tirzepatide improve cardiovascular outcomes and symptoms in patients with obesity and cardiovascular disease?
Answers are grounded in this paper and cite their sources.
Anti-obesity pharmacotherapies represent a disease-modifying approach for obesity-related cardiovascular conditions, particularly HFpEF and AF.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Duru et al. (2026) reported an editorial.
Synapse has enriched 10 related papers. Consider them for comparative context: